The company's portfolio includes SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist for PTSD and stress-induced anxiety, and SP-26, a ketamine implant candidate for fibromyalgia and chronic pain. Silo employs a crypto treasury strategy involving Bitcoin, Ethereum, Solana, and has engaged Fireblocks for digital asset custody.
Cyborg Score Rationale
Silo has a market cap of approximately $4.98 million, and received a Nasdaq non-compliance notice in July 2025 regarding minimum bid price requirements. However, in April 2026 the European Patent Office indicated intent to grant a patent for a preventative therapy targeting the serotonin 4 receptor pathway, licensed from Columbia University, providing strategic IP support.
Top Insights
(April 2026) European Patent Office signaled intent to grant patent for 5-HT4 receptor agonist therapy, strengthening PTSD program IP portfolio
Dual focus on traditional therapeutics and psychedelic-inspired treatments addresses significant unmet needs in CNS disorders and psychiatric conditions
Ultra-low market cap (~$5M) with significant stock volatility; trading well below 52-week high, indicating recovery potential or continued distress
Crypto treasury strategy differentiates company positioning but adds operational and regulatory complexity for micro-cap biotech
Named Competitors
Mindmed — Psychedelic-assisted therapies for PTSD and neuropsychiatric conditions
Compass Pathways — Psilocybin-assisted therapy for treatment-resistant depression
Atara Biotherapeutics — Cell and gene therapies for CNS disorders
Recent Developments
(April 2026) European Patent Office issued Rule 71(3) communication indicating intent to grant patent for novel preventative serotonin 5-HT4 receptor therapy; stock surged 47.5% following announcement
(July 2025) Company received Nasdaq non-compliance notice regarding minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)
Preclinical programs targeting Alzheimer's disease and multiple sclerosis; options agreements with University of Maryland Baltimore and licensing agreements with Columbia University
Open the full interactive Silo Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.